Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, announced its participation in a panel titled "Novel Oncology Targets" at the 43rd Annual Cowen Healthcare Conference, scheduled for March 7, 2023, at 9:10 a.m. ET. CEO John Valliant, Ph.D. will represent the company during this event. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-presentation. Fusion focuses on next-generation radiopharmaceuticals, including its clinical pipeline with products targeting prostate cancer and other malignancies. The company also collaborates with AstraZeneca and Merck for novel therapies.

HAMILTON, ON and BOSTON, March 2, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a panel titled, "Novel Oncology Targets" at the 43^rd Annual Cowen Healthcare Conference on Tuesday, March 7, 2023 at 9:10 a.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.  

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 30 days following their respective presentation dates.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the company has signed strategic actinium supply agreements with TRIUMF, Niowave and BWXT Medical.

Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-43rd-annual-cowen-healthcare-conference-301761582.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When will Fusion Pharmaceuticals present at the Cowen Healthcare Conference?

Fusion Pharmaceuticals will present at the Cowen Healthcare Conference on March 7, 2023, at 9:10 a.m. ET.

Who will represent Fusion Pharmaceuticals at the conference?

CEO John Valliant, Ph.D. will represent Fusion Pharmaceuticals at the conference.

How can I watch the Fusion Pharmaceuticals presentation?

You can watch the live webcast of Fusion Pharmaceuticals' presentation on their website under the Events and Presentations section.

What is the focus of Fusion Pharmaceuticals?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines targeting cancer.

What collaborations does Fusion Pharmaceuticals have?

Fusion Pharmaceuticals collaborates with AstraZeneca and Merck to develop targeted alpha therapies and combination programs.